Evrim Gurpinar

1.3k total citations · 1 hit paper
11 papers, 952 citations indexed

About

Evrim Gurpinar is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Evrim Gurpinar has authored 11 papers receiving a total of 952 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Pharmacology and 3 papers in Organic Chemistry. Recurrent topics in Evrim Gurpinar's work include Inflammatory mediators and NSAID effects (4 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Synthesis and biological activity (2 papers). Evrim Gurpinar is often cited by papers focused on Inflammatory mediators and NSAID effects (4 papers), Bioactive Compounds and Antitumor Agents (2 papers) and Synthesis and biological activity (2 papers). Evrim Gurpinar collaborates with scholars based in United States, Egypt and United Kingdom. Evrim Gurpinar's co-authors include Gary A. Piazza, William E. Grizzle, Courtney Davis, Elita Poplavska, Ajay Aggarwal, Ashlyn Pinto, Huseyin Naci, Karen H. Vousden, Adam B. Keeton and Xi Chen and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and BMJ.

In The Last Decade

Evrim Gurpinar

11 papers receiving 930 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

2017 376 citations Courtney Davis, Huseyin Naci et al. BMJ profile →

Peers

Countries citing papers authored by Evrim Gurpinar

Since Specialization

Citations

This map shows the geographic impact of Evrim Gurpinar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evrim Gurpinar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evrim Gurpinar more than expected).

Fields of papers citing papers by Evrim Gurpinar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evrim Gurpinar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evrim Gurpinar. The network helps show where Evrim Gurpinar may publish in the future.

Co-authorship network of co-authors of Evrim Gurpinar

This figure shows the co-authorship network connecting the top 25 collaborators of Evrim Gurpinar. A scholar is included among the top collaborators of Evrim Gurpinar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evrim Gurpinar. Evrim Gurpinar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 breakdown → 2017 ·BMJ ·Courtney Davis, Huseyin Naci, Evrim Gurpinar, Elita Poplavska, Ashlyn Pinto, Ajay Aggarwal	376
2	Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling 2017 ·Oncotarget ·Bing Zhu, (unknown), Nan Li, Kevin Lee, Verónica Ramírez‐Alcántara, Joshua C. Canzoneri, Alexandra M. Fajardo, Luciana Madeira da Silva, (unknown), John T. Piazza, Larry Yet, (unknown), Evrim Gurpinar, Dennis Otali, William E. Grizzle, (unknown), Xi Chen, Adam B. Keeton, Gary A. Piazza	34
3	Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation 2015 ·Trends in Cell Biology ·Evrim Gurpinar, Karen H. Vousden	73
4	Phosphodiesterase 10, a novel target in colon cancer. 2014 ·Journal of Clinical Oncology ·Suzanne Russo, Li Nan, Kevin Lee, Yaguang Xi, Bing Zhu, Bernard D. Gary, Veronica Ramirez, Evrim Gurpinar, (unknown), Alexandra M. Fajardo, (unknown), John T. Piazza, Xi Chen, Joel Andrews, Yonghe Li, (unknown), Larry Yet, Adam B. Keeton, William E. Grizzle, Gary A. Piazza	2
5	Trisubstituted and tetrasubstituted pyrazolines as a novel class of cell-growth inhibitors in tumor cells with wild type p53 2013 ·Bioorganic & Medicinal Chemistry ·Mohammad Abdel‐Halim, Adam B. Keeton, Evrim Gurpinar, Bernard D. Gary, Simon Vogel, Matthias Engel, Gary A. Piazza, Frank M. Boeckler, Rolf W. Hartmann, Alireza Abadi	5
6	COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs 2013 ·Frontiers in Oncology ·Evrim Gurpinar, William E. Grizzle, Gary A. Piazza	105
7	A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy 2013 ·Molecular Cancer Therapeutics ·Evrim Gurpinar, William E. Grizzle, John J. Shacka, (unknown), Li Nan, (unknown), Suzanne Russo, Adam B. Keeton, Gary A. Piazza	36
8	Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling 2013 ·Molecular Cancer Therapeutics ·Nan Li, Yaguang Xi, Heather N. Tinsley, Evrim Gurpinar, Bernard D. Gary, Bing Zhu, Yonghe Li, Xi Chen, Adam B. Keeton, Alireza Abadi, Mary Pat Moyer, William E. Grizzle, Wen‐Chi Chang, Margie L. Clapper, Gary A. Piazza	112
9	NSAIDs Inhibit Tumorigenesis, but How? 2013 ·Clinical Cancer Research ·Evrim Gurpinar, William E. Grizzle, Gary A. Piazza	180
10	Development and validation of an HPLC method for quantitation of BA‐TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice 2010 ·Biomedical Chromatography ·Haibo Li, (unknown), Xiangrong Zhang, Wei Wang, Hongxia Xu, Elizabeth R. Rayburn, Xu Zhang, Evrim Gurpinar, Xinyi Yang, Charnell I. Sommers, Sadanandan E. Velu, Ruiwen Zhang	7
11	Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent 2010 ·Marine Drugs ·(unknown), Haibo Li, Hongxia Xu, Xiangrong Zhang, Evrim Gurpinar, Xu Zhang, Elizabeth R. Rayburn, Charnell I. Sommers, Xinyi Yang, Sadanandan E. Velu, Wéi Wang, Ruiwen Zhang	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact